Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 7/20 | 0.44 |
| ▸ | CDK1 | P06493 | 7/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 7/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15045451 | 0.77 | GSK3B (0.46) | GSK3BCCNB2CDK1CCNB1CDK5 | |
| SCHEMBL12066538 | 0.77 | CA12 (0.34) | RAB9ASMN1; SMN2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL13561536 | 0.76 | POLB (0.49) | RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL26998804 | 0.74 | PDE3B (0.50) | GSK3BCCNB2CDK1CCNB1CDK5 | |
| SCHEMBL15042818 | 0.71 | MEN1 (0.35) | GSK3BCCNB2CDK1CCNB1CDK5 | |
| SCHEMBL15045568 | 0.70 | MMP12 (0.42) | GSK3BCCNB2CDK1CCNB1CDK5 | |
| SCHEMBL2756736 | 0.69 | TYMS (0.42) | RAB9ASMN1; SMN2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL15045583 | 0.69 | PGR (0.37) | RAB9ASMN1; SMN2BRD4KDM4EALDH1A1 | |
| SCHEMBL10274620 | 0.68 | EPHX2 (0.55) | GSK3BCCNB2CDK1CCNB1CDK5 | |
| SCHEMBL10141060 | 0.67 | PARP10 (0.40) | CDK1CCNB1CDK5CDK5R1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796705-B2 | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | SCHERING CORPORATION | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | HAVCR2, ELOC, ZC3HAV1 | GSK3B 4423/4885CCNB2 2769/4885CDK1 2292/4885 |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ZC3HAV1, HAVCR2, ZC3HAV1L | GSK3B 3621/4885CCNB2 2225/4885CDK1 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.